Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)

被引：3

作者：

Sznol, M. ^{[1
]}

Ferrucci, P. F. ^{[2
]}

Hogg, D. ^{[3
]}

Atkins, M. ^{[4
]}

Wolter, P. ^{[5
]}

Guidoboni, M. ^{[6
]}

Lebbe, C. ^{[7
]}

Kirkwood, J. ^{[8
]}

Schachter, J. ^{[9
]}

Daniels, G. ^{[10
]}

Hassel, J. ^{[11
]}

Cebon, J. ^{[12
]}

Gerritsen, W. ^{[13
]}

Atkinson, V. ^{[14
,15
]}

Thomas, L. ^{[16
]}

McCaffrey, J. ^{[17
]}

Power, D. ^{[18
]}

Jiang, J. ^{[19
]}

Hodi, F. S. ^{[20
]}

Wolchok, J. ^{[21
]}

机构：

[1] Yale Univ, Sch Med Med Oncol, Med Oncol, New Haven, CT USA

[2] Ist Europeo Oncol, Melanoma & Sarcoma, Milan, Italy

[3] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON, Canada

[4] Georgetown Univ, Hematol Oncol, Lombardi Canc Ctr, Washington, DC USA

[5] Univ Hosp Leuven, Dept Gen Med Oncol, Campus Gasthuisberg, Leuven, Belgium

[6] Ist Tumori Romagna IRST, Immunotherapy Unit, Meldola, Italy

[7] Hop St Louis, Dermatol, Paris, France

[8] Hillman Canc Ctr, Med Oncol & Hematol, Pittsburgh, PA USA

[9] Sheba Med Ctr, Ella Lemelbaum Inst Melanoma, Ramat Gan, Israel

[10] Moores UCSD Canc Ctr, Med, La Jolla, CA USA

[11] Univ Heidelberg Hosp, Oncol, Heidelberg, Germany

[12] Olivia Newton John Canc Res Inst, Canc Immunobiol, Heidelberg, Australia

[13] Radboud Univ Nijmegen, Med Ctr Nijmegen, Dept Med Oncol, Nijmegen, Netherlands

[14] Gallipoli Med Res Fdn, Oncol, Greenslopes, Australia

[15] Princess Alexandra Hosp, Greenslopes, Australia

[16] Ctr Hosp Lyon Sud, Dermatol, Pierre Benite, France

[17] Irish Clin Oncol Res Grp, Med Oncol, Dublin, Ireland

[18] Irish Clin Oncol Res Grp, Med Oncol, Cork, Ireland

[19] BMS, Oncol, Princeton, NJ USA

[20] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA

[21] Mem Sloan Kettering Canc Ctr, Ludwig Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw379.18

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1123P

引用

页数：1

共 50 条

[11] Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL). [J].

Hogg, David ;

Chapman, Paul B. ;

Sznol, Mario ;

Lao, Christopher D. ;

Gonzalez, Rene ;

Daniels, Gregory A. ;

Smylie, Michael ;

Kudchadkar, Ragini Reiney ;

Thompson, John A. ;

Sharfman, William Howard ;

Atkins, Michael B. ;

Pavlick, Anna C. ;

Jiang, Joel ;

Avila, Alexandre ;

Demelo, Sheena ;

Hodi, F. Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[12] Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma [J].

Sznol, Mario ;

Ferrucci, Pier Francesco ;

Hogg, David ;

Atkins, Michael B. ;

Wolter, Pascal ;

Guidoboni, Massimo ;

Lebbe, Celeste ;

Kirkwood, John M. ;

Schachter, Jacob ;

Daniels, Gregory A. ;

Hassel, Jessica ;

Cebon, Jonathan ;

Gerritsen, Winald ;

Atkinson, Victoria ;

Thomas, Luc ;

McCaffrey, John ;

Power, Derek ;

Walker, Dana ;

Bhore, Rafia ;

Jiang, Joel ;

Hodi, F. Stephen ;

Wolchok, Jedd D. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (34) :3815-+

[13] CLINICAL RESPONSE, PROGRESSION-FREE SURVIVAL (PFS) AND SAFETY IN PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) RECEIVING NIVOLUMAB (NIVO) COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI MONOTHERAPY IN CHECKMATE 069 STUDY [J].

Hodi, F. Stephen ;

Postow, Michael A. ;

Chesney, Jason ;

Pavlik, Anna C. ;

Robert, Caroline ;

Grossman, Kenneth ;

McDermott, David ;

Linette, Gerald ;

Meyer, Nicolas ;

Giguere, Jeffrey K. ;

Agarwala, Sanjiv S. ;

Shaheen, Montaser ;

Ernstoff, Marc S. ;

Minor, David ;

Salama, April K. ;

Taylor, Matthew ;

Ott, Patrick A. ;

Horak, Christine ;

Gagnier, Paul ;

Wolchok, Jedd D. .

Asia-Pacific Journal of Clinical Oncology, 2015, 11 :109-109

[14] Phase 2 study to evaluate efficacy and safety of combination therapy with nivolumab (NIVO) and ipilimumab(IPI) in patients with previously untreated melanoma [J].

Kiyohara, Y. ;

Takenouchi, T. ;

Uhara, H. ;

Koga, H. ;

Uchi, H. ;

Yamazaki, N. .

ANNALS OF ONCOLOGY, 2017, 28

[15] Effect of nivolumab (NIVO) in combination with ipilimumab (IPI) versus IPI alone on quality of life (QoL) in patients (pts) with treatment-naive advanced melanoma (MEL): Results of a phase II study (CheckMate 069) [J].

Abernethy, Amy Pickar ;

Postow, Michael Andrew ;

Chesney, Jason Alan ;

Grossmann, Kenneth F. ;

Taylor, Fiona ;

Coon, Cheryl ;

Gilloteau, Isabelle ;

Dastani, Homa ;

Gagnier, Paul ;

Robert, Caroline .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[16] CHECKMATE 067: A PHASE III RANDOMIZED DOUBLE-BLIND STUDY OF NIVOLUMAB (NIVO) MONOTHERAPY OR NIVO COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI MONOTHERAPY IN PREVIOUSLY UNTREATED PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) [J].

Wolchok, J. D. ;

Chiarion-Sileni, V. ;

Gonzalez, R. ;

Rutkowski, P. ;

Grob, J. J. ;

Cowey, C. L. ;

Lao, C. D. ;

Schadendorf, D. ;

Ferrucci, P. F. ;

Smylie, M. ;

Dummer, R. ;

Hill, A. ;

Haanen, J. ;

Maio, M. ;

McArthur, G. ;

Yang, A. ;

Rollin, L. ;

Horak, C. ;

Larkin, J. ;

Hodi, F. S. .

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 :68-68

[17] CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL) [J].

Wolchok, J. D. ;

Chiarion-Sileni, V. ;

Gonzalez, R. ;

Rutkowski, P. ;

Grob, J. ;

Cowey, C. L. ;

Lao, C. D. ;

Schadendorf, D. ;

Ferrucci, P. F. ;

Smylie, M. ;

Dummer, R. ;

Hill, A. ;

Haanen, J. ;

Maio, M. ;

McArthur, G. ;

Yang, A. ;

Rollin, L. ;

Horak, C. ;

Larkin, J. ;

Hodi, F. S. .

ANNALS OF ONCOLOGY, 2015, 26 :28-28

[18] Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). [J].

Wolchok, Jedd D. ;

Chiarion-Sileni, Vanna ;

Gonzalez, Rene ;

Rutkowski, Piotr ;

Grob, Jean Jacques ;

Cowey, Charles Lance ;

Lao, Christopher D. ;

Schadendorf, Dirk ;

Ferrucci, Pier Francesco ;

Smylie, Michael ;

Dummer, Reinhard ;

Hill, Andrew Graham ;

Haanen, John B. A. G. ;

Maio, Michele ;

McArthur, Grant A. ;

Yang, Arvin ;

Rollin, Linda ;

Horak, Christine E. ;

Larkin, James M. G. ;

Hodi, F. Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[19] Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. [J].

Hodi, F. Stephen ;

Postow, Michael Andrew ;

Chesney, Jason Alan ;

Pavlick, Anna C. ;

Robert, Caroline ;

Grossmann, Kenneth F. ;

McDermott, David F. ;

Linette, Gerald P. ;

Meyer, Nicolas ;

Giguere, Jeffrey K. ;

Agarwala, Sanjiv S. ;

Shaheen, Montaser F. ;

Ernstoff, Marc S. ;

Minor, David R. ;

Salama, April ;

Taylor, Matthew Hiram ;

Ott, Patrick Alexander ;

Horak, Christine E. ;

Gagnier, Paul ;

Wolchok, Jedd D. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[20] Overall Survivalwith Nivolumab (NIVO) and Ipilimumab (IPI) Combination Therapy in a Phase III Trial of Advanced Melanoma (CHECKMATE 067) [J].

Larkin, J. ;

Chiarion-Sileni, V. ;

Gonzalez, R. ;

Rutkowski, P. ;

Grob, J-J ;

Cowey, C. L. ;

Lao, C. D. ;

Schadendorf, D. ;

Ferrucci, P. F. ;

Smylie, M. ;

Dummer, R. ;

Hill, A. ;

Haanen, J. ;

Maio, M. ;

McArthur, G. ;

Walker, D. ;

Rollin, L. ;

Horak, C. ;

Hodi, F. S. ;

Wolchok, J. D. .

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 :48-48

← 1 2 3 4 5 →